Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease.

Blokker BA, Maijo M, Echeandia M, Galduroz M, Patterson AM, Ten A, Philo M, Schungel R, Gutierrez-de Juan V, Halilbasic E, Fuchs C, Le Gall G, Milkiewicz M, Milkiewicz P, Banales JM, Rushbrook SM, Mato JM, Trauner M, Müller M, Martínez-Chantar ML, Varela-Rey M, Beraza N.

Hepatology. 2019 Feb;69(2):699-716. doi: 10.1002/hep.30275.

PMID:
30229970
2.

Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis.

Staufer K, Halilbasic E, Hillebrand P, Harm S, Schwarz S, Jaksch P, Kivaranovic D, Klepetko W, Trauner M, Kazemi-Shirazi L.

United European Gastroenterol J. 2018 Aug;6(7):1049-1055. doi: 10.1177/2050640618778381. Epub 2018 May 17.

3.

The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study.

Poetter-Lang S, Staufer K, Baltzer P, Tamandl D, Muin D, Bastati N, Halilbasic E, Hodge JC, Trauner M, Kazemi-Shirazi L, Ba-Ssalamah A.

Eur Radiol. 2019 Feb;29(2):1048-1058. doi: 10.1007/s00330-018-5650-5. Epub 2018 Jul 27.

4.

Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes.

Jha P, McDevitt MT, Halilbasic E, Williams EG, Quiros PM, Gariani K, Sleiman MB, Gupta R, Ulbrich A, Jochem A, Coon JJ, Trauner M, Pagliarini DJ, Auwerx J.

Cell Syst. 2018 Jun 27;6(6):709-721.e6. doi: 10.1016/j.cels.2018.05.009. Epub 2018 Jun 13.

5.

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids.

Fuchs CD, Paumgartner G, Mlitz V, Kunczer V, Halilbasic E, Leditznig N, Wahlström A, Ståhlman M, Thüringer A, Kashofer K, Stojakovic T, Marschall HU, Trauner M.

Gut. 2018 Sep;67(9):1683-1691. doi: 10.1136/gutjnl-2017-314553. Epub 2018 Apr 10.

6.

AQP3 is regulated by PPARγ and JNK in hepatic stellate cells carrying PNPLA3 I148M.

Tardelli M, Bruschi FV, Claudel T, Moreno-Viedma V, Halilbasic E, Marra F, Herac M, Stulnig TM, Trauner M.

Sci Rep. 2017 Nov 7;7(1):14661. doi: 10.1038/s41598-017-14557-9.

7.

Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.

Traussnigg S, Kienbacher C, Gajdošík M, Valkovič L, Halilbasic E, Stift J, Rechling C, Hofer H, Steindl-Munda P, Ferenci P, Wrba F, Trattnig S, Krššák M, Trauner M.

Liver Int. 2017 Oct;37(10):1544-1553. doi: 10.1111/liv.13451. Epub 2017 May 20.

8.

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.

Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group.

J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18.

9.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group.

Gastroenterology. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038. Epub 2017 Mar 6.

10.

Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.

Halilbasic E, Steinacher D, Trauner M.

Dig Dis. 2017;35(3):288-292. doi: 10.1159/000454904. Epub 2017 Mar 1. Review.

PMID:
28249255
11.

New therapeutic concepts in bile acid transport and signaling for management of cholestasis.

Trauner M, Fuchs CD, Halilbasic E, Paumgartner G.

Hepatology. 2017 Apr;65(4):1393-1404. doi: 10.1002/hep.28991. Epub 2017 Mar 7. Review.

PMID:
27997980
12.

Bile acids in regulation of inflammation and immunity: friend or foe?

Zhu C, Fuchs CD, Halilbasic E, Trauner M.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4 Suppl 98):25-31. Epub 2016 Jul 29. Review.

13.

Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.

Halilbasic E, Fuchs C, Traussnigg S, Trauner M.

Dig Dis. 2016;34(5):580-8. doi: 10.1159/000445268. Epub 2016 Jun 22. Review.

PMID:
27332721
14.

32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016.

Langsteger W, Rezaee A, Loidl W, Geinitz HS, Fitz F, Steinmair M, Broinger G, Pallwien-Prettner L, Beheshti M, Imamovic L, Beheshti M, Rendl G, Hackl D, Tsybrovsky O, Steinmair M, Emmanuel K, Moinfar F, Pirich C, Langsteger W, Bytyqi A, Karanikas G, Mayerhöfer M, Koperek O, Niederle B, Hartenbach M, Beyer T, Herrmann K, Czernin J, Rausch I, Rust P, DiFranco MD, Lassen M, Stadlbauer A, Mayerhöfer ME, Hartenbach M, Hacker M, Beyer T, Binzel K, Magnussen R, Wei W, Knopp MU, Flanigan DC, Kaeding C, Knopp MV, Leisser A, Nejabat M, Hartenbach M, Kramer G, Krainer M, Hacker M, Haug A, Lehnert W, Schmidt K, Kimiaei S, Bronzel M, Kluge A, Wright CL, Binzel K, Zhang J, Wuthrick E, Maniawski P, Knopp MV, Blaickner M, Rados E, Huber A, Dulovits M, Kulkarni H, Wiessalla S, Schuchardt C, Baum RP, Knäusl B, Georg D, Bauer M, Wulkersdorfer B, Wadsak W, Philippe C, Haslacher H, Zeitlinger M, Langer O, Bauer M, Feldmann M, Karch R, Wadsak W, Zeitlinger M, Koepp MJ, Asselin MC, Pataraia E, Langer O, Zeilinger M, Philippe C, Dumanic M, Pichler F, Pilz J, Hacker M, Wadsak W, Mitterhauser M, Nics L, Steiner B, Hacker M, Mitterhauser M, Wadsak W, Traxl A, Wanek T, Kryeziu K, Mairinger S, Stanek J, Berger W, Kuntner C, Langer O, Mairinger S, Wanek T, Traxl A, Krohn M, Stanek J, Filip T, Sauberer M, Kuntner C, Pahnke J, Langer O, Svatunek D, Denk C, Wilkovitsch M, Wanek T, Filip T, Kuntner-Hannes C, Fröhlich J, Mikula H, Denk C, Svatunek D, Wanek T, Mairinger S, Stanek J, Filip T, Fröhlich J, Mikula H, Kuntner-Hannes C, Balber T, Singer J, Fazekas J, Rami-Mark C, Berroterán-Infante N, Jensen-Jarolim E, Wadsak W, Hacker M, Viernstein H, Mitterhauser M, Denk C, Svatunek D, Sohr B, Mikula H, Fröhlich J, Wanek T, Kuntner-Hannes C, Filip T, Pfaff S, Philippe C, Mitterhauser M, Hartenbach M, Hacker M, Wadsak W, Wanek T, Halilbasic E, Visentin M, Mairinger S, Stieger B, Kuntner C, Trauner M, Langer O, Lam P, Aistleitner M, Eichinger R, Artner C, Eidherr H, Vraka C, Haug A, Mitterhauser M, Nics L, Hartenbach M, Hacker M, Wadsak W, Kvaternik H, Müller R, Hausberger D, Zink C, Aigner RM, Cossío U, Asensio M, Montes A, Akhtar S, Te Welscher Y, van Nostrum R, Gómez-Vallejo V, Llop J, VandeVyver F, Barclay T, Lippens N, Troch M, Hehenwarter L, Egger B, Holzmannhofer J, Rodrigues-Radischat M, Pirich C, Pötsch N, Rausch I, Wilhelm D, Weber M, Furtner J, Karanikas G, Wöhrer A, Mitterhauser M, Hacker M, Traub-Weidinger T, Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, Devaux JY, Mohty M, Garderet L, Talbot JN, Stanzel S, Pregartner G, Schwarz T, Bjelic-Radisic V, Liegl-Atzwanger B, Aigner R, Stanzel S, Quehenberger F, Aigner RM, Marković AK, Janković M, Jerković VM, Paskaš M, Pupić G, Džodić R, Popović D, Fornito MC, Familiari D, Koranda P, Polzerová H, Metelková I, Henzlová L, Formánek R, Buriánková E, Kamínek M, Thomson WH, Lewis C, Thomson WH, O'Brien J, James G, Notghi A, Huber H, Stelzmüller I, Wunn R, Mandl M, Fellner F, Lamprecht B, Gabriel M, Fornito MC, Leonardi G, Thomson WH, O'Brien J, James G, Hudzietzová J, Sabol J, Fülöp M.

EJNMMI Res. 2016 Apr;6(Suppl 1):32. doi: 10.1186/s13550-016-0168-9. Epub 2016 Apr 18.

15.

Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.

Wanek T, Halilbasic E, Visentin M, Mairinger S, Römermann K, Stieger B, Kuntner C, Müller M, Langer O, Trauner M.

J Pharm Sci. 2016 Jan;105(1):106-12. doi: 10.1016/j.xphs.2015.11.014. Epub 2016 Jan 13.

PMID:
26852845
16.

Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.

Halilbasic E, Fuchs C, Hofer H, Paumgartner G, Trauner M.

Dig Dis. 2015;33 Suppl 2:149-63. doi: 10.1159/000440827. Epub 2015 Dec 7. Review.

PMID:
26641242
17.

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.

Baghdasaryan A, Fuchs CD, Österreicher CH, Lemberger UJ, Halilbasic E, Påhlman I, Graffner H, Krones E, Fickert P, Wahlström A, Ståhlman M, Paumgartner G, Marschall HU, Trauner M.

J Hepatol. 2016 Mar;64(3):674-81. doi: 10.1016/j.jhep.2015.10.024. Epub 2015 Oct 31.

18.

Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.

Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.

Dig Dis. 2015;33(4):598-607. doi: 10.1159/000375353. Epub 2015 Jul 6. Review.

PMID:
26159280
19.

Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.

Trauner M, Halilbasic E, Claudel T, Steinacher D, Fuchs C, Moustafa T, Pollheimer M, Krones E, Kienbacher C, Traussnigg S, Kazemi-Shirazi L, Munda P, Hofer H, Fickert P, Paumgartner G.

Dig Dis. 2015;33(3):433-9. doi: 10.1159/000371904. Epub 2015 May 27. Review.

PMID:
26045280
20.

Phosphatidylcholine contributes to in vivo (31)P MRS signal from the human liver.

Chmelík M, Valkovič L, Wolf P, Bogner W, Gajdošík M, Halilbasic E, Gruber S, Trauner M, Krebs M, Trattnig S, Krššák M.

Eur Radiol. 2015 Jul;25(7):2059-66. doi: 10.1007/s00330-014-3578-y. Epub 2015 Jan 11.

PMID:
25576233
21.

Cystic fibrosis related liver disease--another black box in hepatology.

Staufer K, Halilbasic E, Trauner M, Kazemi-Shirazi L.

Int J Mol Sci. 2014 Aug 4;15(8):13529-49. doi: 10.3390/ijms150813529. Review.

22.

Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.

Trauner M, Halilbasic E, Kazemi-Shirazi L, Kienbacher C, Staufer K, Traussnigg S, Hofer H.

Dig Dis. 2014;32(5):631-6. doi: 10.1159/000360517. Epub 2014 Jul 14. Review.

PMID:
25034298
23.

Fibrate treatment for primary biliary cirrhosis.

Cuperus FJ, Halilbasic E, Trauner M.

Curr Opin Gastroenterol. 2014 May;30(3):279-86. doi: 10.1097/MOG.0000000000000056. Review.

PMID:
24625898
24.

The role of canalicular ABC transporters in cholestasis.

Cuperus FJ, Claudel T, Gautherot J, Halilbasic E, Trauner M.

Drug Metab Dispos. 2014 Apr;42(4):546-60. doi: 10.1124/dmd.113.056358. Epub 2014 Jan 28. Review.

PMID:
24474736
25.

SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling.

García-Rodríguez JL, Barbier-Torres L, Fernández-Álvarez S, Gutiérrez-de Juan V, Monte MJ, Halilbasic E, Herranz D, Álvarez L, Aspichueta P, Marín JJ, Trauner M, Mato JM, Serrano M, Beraza N, Martínez-Chantar ML.

Hepatology. 2014 May;59(5):1972-83. doi: 10.1002/hep.26971. Epub 2014 Mar 31.

26.

Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia.

Jha P, Claudel T, Baghdasaryan A, Mueller M, Halilbasic E, Das SK, Lass A, Zimmermann R, Zechner R, Hoefler G, Trauner M.

Hepatology. 2014 Mar;59(3):858-69. doi: 10.1002/hep.26732. Epub 2014 Jan 28.

PMID:
24002947
27.

Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice.

Fickert P, Krones E, Pollheimer MJ, Thueringer A, Moustafa T, Silbert D, Halilbasic E, Yang M, Jaeschke H, Stokman G, Wells RG, Eller K, Rosenkranz AR, Eggertsen G, Wagner CA, Langner C, Denk H, Trauner M.

Hepatology. 2013 Dec;58(6):2056-69. doi: 10.1002/hep.26599. Epub 2013 Oct 15.

PMID:
23813550
28.

Nuclear receptors as drug targets in cholestatic liver diseases.

Halilbasic E, Baghdasaryan A, Trauner M.

Clin Liver Dis. 2013 May;17(2):161-89. doi: 10.1016/j.cld.2012.12.001. Review.

29.

Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.

Fickert P, Pollheimer MJ, Silbert D, Moustafa T, Halilbasic E, Krones E, Durchschein F, Thüringer A, Zollner G, Denk H, Trauner M.

J Hepatol. 2013 Jun;58(6):1201-8. doi: 10.1016/j.jhep.2013.01.026. Epub 2013 Jan 29.

30.

Mechanisms and functional consequences of liver failure substantially differ between endotoxaemia and faecal peritonitis in rats.

Recknagel P, Gonnert FA, Halilbasic E, Gajda M, Jbeily N, Lupp A, Rubio I, Claus RA, Kortgen A, Trauner M, Singer M, Bauer M.

Liver Int. 2013 Feb;33(2):283-93. doi: 10.1111/liv.12012. Epub 2012 Nov 12.

PMID:
23146068
31.

Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment.

Trauner M, Halilbasic E, Baghdasaryan A, Moustafa T, Krones E, Fickert P, Hofer H, Penner E.

Dig Dis. 2012;30 Suppl 1:39-47. doi: 10.1159/000341123. Epub 2012 Oct 11. Review.

PMID:
23075867
32.

Bile acid transporters and regulatory nuclear receptors in the liver and beyond.

Halilbasic E, Claudel T, Trauner M.

J Hepatol. 2013 Jan;58(1):155-68. doi: 10.1016/j.jhep.2012.08.002. Epub 2012 Aug 8. Review.

33.

Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice.

Fuchs CD, Claudel T, Kumari P, Haemmerle G, Pollheimer MJ, Stojakovic T, Scharnagl H, Halilbasic E, Gumhold J, Silbert D, Koefeler H, Trauner M.

Hepatology. 2012 Jul;56(1):270-80. doi: 10.1002/hep.25601. Epub 2012 May 29.

PMID:
22271167
34.

Pathogenesis of primary sclerosing cholangitis.

Pollheimer MJ, Halilbasic E, Fickert P, Trauner M.

Best Pract Res Clin Gastroenterol. 2011 Dec;25(6):727-39. doi: 10.1016/j.bpg.2011.10.009. Review.

35.

Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.

Modica S, Petruzzelli M, Bellafante E, Murzilli S, Salvatore L, Celli N, Di Tullio G, Palasciano G, Moustafa T, Halilbasic E, Trauner M, Moschetta A.

Gastroenterology. 2012 Feb;142(2):355-65.e1-4. doi: 10.1053/j.gastro.2011.10.028. Epub 2011 Nov 2.

PMID:
22057115
36.

Targeting nuclear bile acid receptors for liver disease.

Trauner M, Baghdasaryan A, Claudel T, Fickert P, Halilbasic E, Moustafa T, Zollner G.

Dig Dis. 2011;29(1):98-102. doi: 10.1159/000324141. Epub 2011 Jun 17. Review.

PMID:
21691114
37.

Nuclear receptors as new perspective for the management of liver diseases.

Trauner M, Halilbasic E.

Gastroenterology. 2011 Apr;140(4):1120-1125.e1-12. doi: 10.1053/j.gastro.2011.02.044. Epub 2011 Feb 18. Review.

PMID:
21334334
38.

New insights into autoimmune cholangitis through animal models.

Trauner M, Fickert P, Baghdasaryan A, Claudel T, Halilbasic E, Moustafa T, Wagner M, Zollner G.

Dig Dis. 2010;28(1):99-104. doi: 10.1159/000282072. Epub 2010 May 7. Review.

PMID:
20460897
39.

Complications following autologous latissimus flap breast reconstruction.

Burgic M, Bruant Rodier C, Wilk A, Bodin F, Rifatbegović A, Halilbasic E, Burgic M, Brkic E, Avdagic H.

Bosn J Basic Med Sci. 2010 Feb;10(1):65-7.

40.

Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.

Fickert P, Fuchsbichler A, Moustafa T, Wagner M, Zollner G, Halilbasic E, Stöger U, Arrese M, Pizarro M, Solís N, Carrasco G, Caligiuri A, Sombetzki M, Reisinger E, Tsybrovskyy O, Zatloukal K, Denk H, Jaeschke H, Pinzani M, Trauner M.

Am J Pathol. 2009 Dec;175(6):2392-405. doi: 10.2353/ajpath.2009.090114. Epub 2009 Nov 12. Erratum in: Am J Pathol. 2010 May;176(5):2581.

41.

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.

Halilbasic E, Fiorotto R, Fickert P, Marschall HU, Moustafa T, Spirli C, Fuchsbichler A, Gumhold J, Silbert D, Zatloukal K, Langner C, Maitra U, Denk H, Hofmann AF, Strazzabosco M, Trauner M.

Hepatology. 2009 Jun;49(6):1972-81. doi: 10.1002/hep.22891.

42.

Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.

Trauner M, Fickert P, Halilbasic E, Moustafa T.

Wien Med Wochenschr. 2008;158(19-20):542-8. doi: 10.1007/s10354-008-0592-1. Review.

PMID:
18998069
43.

Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice.

Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Hörl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M.

Liver Int. 2008 Aug;28(7):948-58. doi: 10.1111/j.1478-3231.2008.01758.x. Epub 2008 Apr 11.

PMID:
18410282
44.

Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.

Zollner G, Wagner M, Moustafa T, Fickert P, Silbert D, Gumhold J, Fuchsbichler A, Halilbasic E, Denk H, Marschall HU, Trauner M.

Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G923-32. Epub 2005 Dec 15.

45.

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.

Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M.

Hepatology. 2005 Aug;42(2):420-30.

PMID:
15986414

Supplemental Content

Loading ...
Support Center